April 8, 2021

Journal of Medicinal Chemistry

Discovery of AG-270, a First-in-Class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous MTAP Deletion

April 1, 2021

Blood

Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study

January 14, 2021

Cancer Cell

MAT2A Inhibition Blocks the Growth of MTAP-deleted Cancer Cells By Reducing PRMT5-dependent mRNA Splicing and Inducing DNA damage

October 29, 2020

Journal of Clinical Oncology

Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination with Azacitidine for Newly Diagnosed Acute Myeloid Leukemia

July 27, 2020

CNS Oncology

Ivosidenib, an IDH1 Inhibitor, in a patient with recurrent, IDH1-mutant glioblastoma: A Case Report from a Phase 1 Study

June 12, 2020

Journal of Clinical Oncology

Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Advanced Glioma

May 25, 2020

Nature

Comparative evaluation of itaconate and its derivatives reveals divergent inflammasome and type I interferon regulation in macrophages

May 13, 2020

The Lancet Oncology

Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicenter, randomized, double-blind, placebo-controlled, phase 3 study

May 13, 2020

Blood Advances

Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML

April 15, 2020

Cancer Chemother Pharmacol

Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation

March 24, 2020

Journal of Clinical Oncology

Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma

February 13, 2020

Blood

Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia

January 22, 2020

ACS Medicinal Chemistry Letters

Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma

June 21, 2018

New England Journal of Medicine

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML

April 15, 2018

ACS Medicinal Chemistry Letters

Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers

January 19, 2018

ACS Medicinal Chemistry Letters

Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers

More from Servier

Research & Development

We invest in the research and development of innovative medicines, all designed with the goal to best address the unmet needs of patients. 

Learn More

Clinical Trials

We strive to have consistent and concise transparency throughout all our clinical trials and research and development for the benefit of our patients.

Learn More

Medicines

Servier Pharmaceuticals' medicines change the lives of the patients we serve. Currently, within the United States, oncology treatment and care are our immediate focus.

Learn More